Exelixis
EXEL
#1695
Rank
โ‚ฌ9.49 B
Marketcap
33,24ย โ‚ฌ
Share price
0.52%
Change (1 day)
71.45%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024โ‚ฌ9.41 M45.17%
2023โ‚ฌ6.48 M-41.81%
2022โ‚ฌ11.14 M-31.9%
2021โ‚ฌ16.36 M-20.71%
2020โ‚ฌ20.64 M303.63%
2019โ‚ฌ5.11 M-70.5%
2018โ‚ฌ17.33 M8.82%
2017โ‚ฌ15.92 M-17.35%
2016โ‚ฌ19.27 M-75.68%
2015โ‚ฌ79.23 M19.37%
2014โ‚ฌ66.37 M258.49%
2013โ‚ฌ18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
โ‚ฌ25.89 Mโ‚ฌ55.2 M๐Ÿ‡ฌ๐Ÿ‡ง UK
โ‚ฌ11.64 Mโ‚ฌ71.88 M๐Ÿ‡ซ๐Ÿ‡ท France
โ‚ฌ14.45 Mโ‚ฌ88.44 M๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ29.95 Mโ‚ฌ0.31 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ48.74 Mโ‚ฌ0.23 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ70.18 Mโ‚ฌ0.32 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ50.21 Mโ‚ฌ0.38 B๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚ฌ0.19 Mโ‚ฌ1.32 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/Aโ‚ฌ0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA